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A B S T R A C T
Epilepsy is a chronic neurological disorder affecting nearly 65–70 million people worldwide. Despite the ob-
served advances in the development of new antiepileptic drugs (AEDs), still about 30–40% of patients cannot
achieve a satisfactory seizure control. In our current research, we aimed at using the combined results of
radioligand binding experiments, PAMPA-BBB assay and animal experimentations in order to design a group of
compounds that exhibit broad spectrum of anticonvulsant activity. The synthesized 4-alkyl-5-substituted-1,2,4-
triazole-3-thione derivatives were primarily screened in the maximal electroshock-induced seizure (MES) test in
mice. Next, the most promising compounds (17, 22) were investigated in 6 Hz (32 mA) psychomotor seizure
model. Protective effect of compound 22 was almost similar to that of levetiracetam. Moreover, these com-
pounds did not induce genotoxic and hemolytic changes in human cells as well as they were characterized by low
cellular toxicity. Taking into account the structural requirements for good anticonvulsant activity of 4-alkyl-5-
aryl-1,2,4-triazole-3-thiones, it is visible that small electron-withdrawing substituents attached to phenyl ring
have beneficial effects both on affinity towards VGSCs and protective activity in the animal models of epilepsy.
1. Introduction
Epilepsy is a chronic neurological disorder affecting nearly 65–70
million people worldwide [1]. Epileptics not only suffer from the dis-
ease’s symptoms, but they are also at an increased risk of death [2].
Treatment of epilepsy is based mainly on the properly selected phar-
macotherapy. However, despite the observed advances in the devel-
opment of new antiepileptic drugs (AEDs), still about 30–40% of pa-
tients cannot achieve a satisfactory seizure control [3]. New AEDs
usually have milder side-effects, better pharmacokinetic profile and
slightly improved efficiency. Unfortunately, these drugs have not sig-
nificantly improved the outcome of treatment in patients with therapy-
resistant epilepsy. Hence, there is an immense need for new AEDs ex-
hibiting efficiency against a broad spectrum of seizures.
In our recent papers, we have identified 4-alkyl-5-aryl-1,2,4-tria-
zole-3-thiones as a promising group of antiepileptic drug candidates
[4–7]. It has been proved that anticonvulsant activity of these com-
pounds is due to their ability to interact with the voltage-gated sodium
channels (VGSCs) [6,7]. Moreover, 4-alkyl-5-aryl-1,2,4-triazole-3-
thione derivatives possessed favorable pharmacological and tox-
icological profile, including low neurotoxicity and toxicity against
human cells, lack of genotoxic properties, fast onset of action, sus-
tainable activity over time, and ability to potentiate the anticonvulsant
activity of valproate [7,8]. The effect of the alkyl chain structure on the
pharmacological activity, toxicity, ability to penetrate the blood-brain
barrier, and the affinity towards VGSCs has been well-investigated and
discussed in our previous articles [4–7]. 1,2,4-Triazole derivatives with
unbranched alkyl chains, containing from 4 to 7 carbon atoms, turned
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out to possess the most beneficial activity during preclinical studies.
However, still little is known about the effects of structural modifica-
tions of the aryl moiety attached to 1,2,4-triazole-3-thione core on the
anticonvulsant activity since only compounds with 3-chlorophenyl
substituent (with or without a methylene linker) have been tested thus
far (Fig. 1).
Additionally, these derivatives were tested only in the mouse
maximal electroshock-induced seizure (MES) test, which is recognized
model of generalized tonic-clonic seizures in humans. The ability of
these compounds to inhibit seizures in other types of epilepsy would
significantly improve the chances of 1,2,4-triazole derivatives to be
investigated in further stages of drug development process. Therefore,
in our current studies, we aimed to comprehensively analyze the role of
aryl moiety attached to 1,2,4-triazole-3-thione in binding to molecular
target and anticonvulsant effect of the synthesized compounds. The
most promising 1,2,4-triazole derivatives were also evaluated in the
mouse 6 Hz (32 mA) model of psychomotor seizures. We believe that
the results presented in this manuscript will provide valuable insights
on the design and development of new AED candidates.
2. Results and discussion
2.1. Chemistry
The investigated compounds were synthesized in moderate to high
yields (i.e., 48–90%), starting from the respective carboxylic acids
(Scheme 1). These acids were converted into the corresponding esters,
which subsequently were subjected to hydrazinolysis in order to obtain
carboxylic acid hydrazides. Reaction between respective hydrazides
and alkyl isothiocyanates resulted in 1,4-disubstituted thiosemicarba-
zide derivatives. Dehydrocyclization of the respective thiosemicarba-
zides in an alkaline environment led to the formation of 4-alkyl-5-
substituted-1,2,4-triazole-3-thiones (1–22). The purity of the title
compounds was checked using elemental analysis (C, H, N), while their
structures were elucidated on the basis of 1H- and 13C NMR spectra. The
obtained results of the elemental analyses were within ± 0.4% of the
theoretical values. The results of spectral analyses of the intermediates
(i.e., 1,4-disubstituted thiosemicarbazides) are given as Supplementary
Material.
2.2. Anticonvulsant activity
From the hitherto synthesized 4-alkyl-5-substituted-1,2,4-triazole-3-
thiones, which had protective effect in mouse MES model of epilepsy,
all possessed electron-withdrawing groups (EWGs) at the phenyl ring
attached to 1,2,4-triazole core [4–7]. Therefore, in order to examine the
effect of structural modifications of aryl substituent on the antic-
onvulsant activity of 1,2,4-triazole-based derivatives, a series of com-
pounds (1–8) with electron-donating groups (EDGs) were obtained in
the first stage of the study. EDGs differed in their electron-donating
properties (eOH, eOCH3) and position in the phenyl ring.
Among 1,2,4-triazoles (1–8), only a few compounds exhibited weak
protective activity against MES-induced seizures (Table 1). This in-
dicates that EDGs (regardless of their location) negatively affect their
anticonvulsant activity measured in the MES test in mice. Therefore,
during further studies the EWGs were selected for structure modifica-
tions. Only bromine and fluorine derivatives were synthesized (Table 2)
since the role of chlorophenyl moiety, with or without a methylene
linker, was extensively investigated in our previously published studies
[4,5,7]. To better understand the mechanism of the anticonvulsant ef-
fect (or its lack) of the compounds 1–22, an initial evaluation of their
affinity towards the batrachotoxin-binding site of the VGSCs and their
ability to permeate through the blood-brain barrier (BBB) has been
performed (Table 3). These results confirmed that both compounds
containing EDGs and EWGs can be classified as BBB+ (or CNS+) since
good permeation through BBB is expected for compounds with
Pe > 5.19 cm/s [9]. Therefore weak activity of compounds 1–8 in
mouse MES test was associated rather with low or no affinity towards
VGSCs (see Table 3).
The anticonvulsant effect of the compounds containing EWGs
(9–22) was clearly dependent on the type of halogen atom. Smaller
substituents (-F, Cl) appear to have beneficial effect on the protective
Fig. 1. Design of the target compounds based on the results of anticonvulsant activity (ED50), neurotoxicity (TD50) and affinity towards batrachotoxin-binding sites of
VGSCs (IC50) of the most promising 4-alkyl-5-substituted-1,2,4-triazole-3-thione derivatives published so far.
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activity of 1,2,4-triazole-3-thiones in MES test in mice. This can be
associated with their higher affinity towards VGSCs (lower IC50 values
for the chlorine [6,7] and fluorine derivatives). Compounds with bro-
mophenyl substituents (9–14) mostly possessed weak or no antic-
onvulsant activity (Table 2). Notably, fluorophenyl derivatives (15–17)
were characterized by much stronger activity than valproate. The
elongation of the alkyl substituent in compounds 15–17 had significant
impact on their affinity towards batrachotoxin-binding site in VGSCs.
Interestingly, both butyl and heptyl derivatives exhibited the same
anticonvulsant potency at their peak activity (ED50 = 67.8 mg/kg), al-
though these compounds showed apparently different affinity for
VGSCs (i.e., 190 vs 18.2 µM). This may suggest the existence of an
additional molecular mechanism responsible for anticonvulsant effect.
Such phenomenon is very common in the case of AEDs. For instance,
the antiepileptic activity of valproic acid and its salts is associated with
blockade of Na+ and T-type Ca2+ channels, inhibition of NMDA re-
ceptors-mediated excitation, enhancement of GABA-ergic neuro-
transmission and stimulation of K+ currents [10].
In our recent studies, we have observed that introduction of a me-
thylene linker into the 4-alkyl-5-aryl-1,2,4-triazole-3-thione derivatives
significantly improved their pharmacological properties and decreased
neurotoxic effects [5,7]. With this in mind, we analyzed the influence of
two types of linkers, i.e., methylene and ethylene ones, on the antic-
onvulsant activity of 4-alkyl-5-(3-fluorophenyl)-1,2,4-triazole-3-
thiones. Contrary to our expectations, the replacement of 3-fluor-
ophenyl moiety by 3-fluorobenzyl group did not result in an increased
efficiency of the obtained compounds (18–20) in the MES test in mice.
Moreover, in the case of heptyl derivative (20) significant decrease in
anticonvulsant activity has been observed. However, the introduction
of methylene linker led to a beneficial time-course profile of antic-
onvulsant potency, similarly as in the case of previously investigated 4-
alkyl-5-(3-chlorobenzyl)-1,2,4-triazole-3-thiones [5]. Respective hexyl
and heptyl derivatives (19, 20) lacked significant fluctuations of an-
ticonvulsant activity at consecutive time points (i.e., 15, 30, 60,
120 min). Since in-vitro studies have shown that introduction of the
ethylene linker leads to a further increase in affinity towards VGSCs,
respective (3-fluorophenyl)ethyl derivatives (21, 22) were also eval-
uated against MES-induced seizures. These compounds were also
characterized by the highest ability to cross the blood-brain barrier as
shown in PAMPA-BBB model (Table 3). Both compounds (21, 22) ex-
hibited stronger anticonvulsant activity than valproate. Additionally, 5-
[(3-fluorophenyl)ethyl]-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione
(22) produced stable anticonvulsant effect, devoid of fluctuations after
its administration to mice. This may confirm the hypothesis formulated
in our earlier paper [5] that the presence of linker between aryl (i.e.,
halogenphenyl) moiety and 1,2,4-triazole core results in a slower
elimination of the compounds from the central nervous system.
The most promising compounds (i.e., 17 and 22), which activity
was above 2-fold higher than that of valproate, were subsequently in-
vestigated in the mouse 6 Hz (32 mA) psychomotor seizure model of
partial epilepsy. The mentioned test is one of a preclinical screening
tool for evaluation of novel AEDs with diverse mechanisms of action. It
has been used for several years and by numerous groups as a model of
refractory epilepsy to evaluate preclinical AEDs pharmacology [11–13].
However, according to Metcalf et al. [14] the 6 Hz (44 mA) seizure test
Scheme 1. Synthetic route to compounds 1–22. Structures of R1 and R2 substituents are given in Tables 1 and 2.
Table 1
Anticonvulsant activity of compounds 1–8 (containing EDGs) in the mouse
maximal electroshock-induced seizure (MES) test.
R1 R2 Pretreatment time
[min]
MES test
ED50 [mg/kg] ± SEM
1. hexyl 15 inactive
30
60
120
2. heptyl 15 > 500
30 430.6 ± 29.6
60 361.8 ± 27.8
120 330.2 ± 21.4
3. hexyl 15 inactive
30
60
120
4. heptyl 15 inactive
30
60
120
5. hexyl 15 374.4 ± 10.9
30 317.2 ± 9.5
60 356.4 ± 19.8
120 370.1 ± 9.6
6. heptyl 15 inactive
30
60
120
7. butyl 15 inactive
30
60
120
8. hexyl 15 462.9 ± 20.0
30 429.5 ± 19.0
60 454.8 ± 24.1
120 460.8 ± 22.6
Valproate 15 189.0 ± 17.3
30 216.9 ± 9.4
60 218.4 ± 18.9
120 246.6 ± 21.4
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Table 2
Anticonvulsant activity and neurotoxicity of compounds 9–22 (containing EWGs) measured in the mouse MES and rotarod tests.
R1 R2 Pretreatment time
[min]
MES test
ED50 [mg/kg] ± SEM
Rotarod test
TD50 [mg/kg] ± SEM
9. butyl 15 inactive nd
30
60
120
10. pentyl 15 inactive nd
30
60
120
11. butyl 15 inactive nd
30
60
120
12. pentyl 15 322.3 ± 22.4 nd
30 353.9 ± 23.9
60 341.0 ± 24.8
120 365.3 ± 24.1
13. butyl 15 283.0 ± 18.4 nd
30 201.0 ± 20.3
60 256.5 ± 29.5
120 316.6 ± 21.9
14. pentyl 15 195.5 ± 21.2 nd
30 263.7 ± 23.9
60 340.8 ± 22.6
120 370.8 ± 21.5
15. butyl 15 67.8 ± 7.6 171.7 ± 21.2
30 123.8 ± 13.3 144.2 ± 21.6
60 144.3 ± 9.5 130.4 ± 17.6
120 153.3 ± 13.6 122.5 ± 19.4
16. hexyl 15 65.2 ± 7.6 120.0 ± 20.3
30 72.1 ± 10.8 204.0 ± 22.9
60 136.0 ± 11.1 246.6 ± 21.5
120 161.1 ± 15.9 320.1 ± 23.6
17. heptyl 15 67.8 ± 7.6 135.6 ± 15.2
30 88.6 ± 9.2 210.9 ± 21.0
60 93.6 ± 9.4 269.2 ± 23.6
120 119.0 ± 9.5 344.7 ± 25.5
18. butyl 15 77.3 ± 16.7 181.7 ± 18.0
30 135.6 ± 15.2 204.6 ± 20.1
60 153.1 ± 20.4 238.0 ± 18.9
120 181.7 ± 18.0 243.0 ± 26.7
19. hexyl 15 127.7 ± 10.0 204.6 ± 20.1
30 119.0 ± 9.5 246.6 ± 21.5
60 130.8 ± 10.3 288.5 ± 19.0
120 134.6 ± 11.8 312.1 ± 20.4
20. heptyl 15 263.7 ± 24.0 356.4 ± 19.8
30 252.4 ± 23.6 347.6 ± 21.4
60 297.2 ± 21.4 339.0 ± 19.0
120 320.1 ± 23.6 362.5 ± 20.3
21. butyl 15 94.4 ± 17.3 246.6 ± 21.8
30 121.3 ± 14.5 255.4 ± 19.9
60 172.5 ± 26.0 269.2 ± 19.3
120 > 200 304.1 ± 24.0
22. hexyl 15 87.5 ± 12.1 309.3 ± 30.0
30 98.3 ± 13.2 288.6 ± 19.0
60 100.0 ± 14.6 288.6 ± 19.0
120 89.6 ± 14.3 290.4 ± 24.5
Valproate 15 189.0 ± 17.3 363.3 ± 14.2
30 216.9 ± 9.4 372.8 ± 16.8
60 218.4 ± 18.9 417.3 ± 9.5
120 246.6 ± 21.4 512.3 ± 20.2
nd – not determined.
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is much more discriminatory pharmacoresistant screening model when
compared to 32 mA.
The latest cohort studies have shown that despite the introduction
of over a dozen of new AEDs, the overall seizure control in patients with
epilepsy has not essentially changed [15]. Vast majority of these new
AEDs are “me-too drugs”, i.e. they are structurally similar to already
known ones. Although “me-too drugs” show a better profile of side
effects and usually offer beneficial pharmacokinetics, it is highly un-
likely that they may constitute an effective alternative in the treatment
of refractory epilepsy. Therefore, 4-alkyl-5-substituted-1,2,4-triazole-3-
thione derivatives, that are structurally unrelated to currently marketed
AEDs have a chance to become promising drug candidates for further
clinical testing. As presented in Table 4, both 17 and 22 turned out to
be highly effective in 6 Hz psychomotor seizure model. It is worth
mentioning that the anticonvulsant activities observed were quite
stable over the investigated periods of time (i.e., 15, 30, 60, 120 min)
(Fig. 2).
Importantly, the protective effect of compound 22 in the above-
mentioned model of psychomotor seizures was much stronger when
Table 3
In-vitro measurement of the ability of the investigated 1,2,4-triazole derivatives
to interact with the batrachotoxin-binding sites of VGSCs and to permeate
through the blood–brain barrier (BBB).
Compound R1 R2 Na+ channel
(site 2) affinity
IC50
[µM] ± SEM
Permeability
coefficients
(Pe × 10−6) ± SD
[cm/s]
1. hexyl > 1000 nd
2. heptyl 740.0 ± 33.0 38.37 ± 2.46
3. hexyl > 1000 nd
5. hexyl 400.0 ± 15.0 56.61 ± 4.72
6. heptyl > 1000 nd
8. hexyl 560.0 ± 12.0 nd
9. butyl > 1000 nd
11. butyl > 1000 nd
12. pentyl 450.0 ± 21.2 nd
13. butyl 286.6 ± 11.7 nd
15. butyl 190.0 ± 11.7 14.50 ± 1.22
16. hexyl 35.0 ± 1.4 nd
17. heptyl 18.2 ± 0.8 8.19 ± 0.41
18. butyl 36.2 ± 3.6 13.87 ± 1.04
19. hexyl 12.2 ± 0.6 14.72 ± 0.81
20. heptyl 19.3 ± 0.6 nd
21. butyl 18.7 ± 1.8 25.54 ± 0.81
22. hexyl 8.8 ± 0.2 54.68 ± 2.14
Valproate nd 15.37 ± 4.71
Table 3 (continued)
Compound R1 R2 Na+ channel
(site 2) affinity
IC50
[µM] ± SEM
Permeability
coefficients
(Pe × 10−6) ± SD
[cm/s]
Veratridine 17.8 ± 0.9 nd
Permeability coefficients were obtained from PAMPA-BBB assay. Affinity to-
wards Na+ channels was evaluated on the basis of the displacement of [3H]
batrachotoxin from its binding site. nd – not determined.
Table 4
Quantitative analysis of anticonvulsant potential of compounds 17 and 22 in
the mouse 6 Hz (32 mA) seizure test.
Compound Pretreatment
time [min]
ED50 ± SEM
[mg/kg]
TD50 ± SEM
[mg/kg]
Protective
index
(TD50/ED50)
17 15 39.3 ± 13.2 135.6 ± 15.2 3.4
30 46.5 ± 9.6 210.9 ± 21.0 4.5
60 53.1 ± 12.1 269.2 ± 23.6 5.1
120 45.3 ± 10.8 344.7 ± 25.5 7.6
22 15 18.6 ± 4.9 309.3 ± 30.0 16.6
30 24.9 ± 7.3 288.6 ± 19.0 11.6
60 33.5 ± 8.9 288.6 ± 19.0 8.6
120 33.5 ± 8.9 290.4 ± 24.5 8.7
Levetiracetam 60 19.4 > 500 (1601) > 25.8
(82.5)
Data for levetiracetam are taken from [11,25].
Fig. 2. Time-course effect of compounds 17 and 22 in the 6 Hz (32 mA) psy-
chomotor seizure test.
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compared to valproate and carbamazepine and was almost similar to
that of levetiracetam, which is considered a model drug in 6 Hz (32 mA)
test [11,16,17] (Table 5). Compound 22 had also substantially better
benefit-to-risk ratio than valproate and carbamazepine as indicated by
the respective PIs values. Out of the AEDs presented in Table 5, only
levetiracetam was found to be much safer than 22 in terms of the im-
pairment of motor coordination evaluated in the rotarod test. According
to Barton et al. [11] TD50 of levetiracetam was higher than 500 mg/kg,
while the experiments performed in our laboratory by Luszczki et al.
[25] gave TD50 as high as 1601 mg/kg.
Considering the structure-activity (and toxicity) relationships, it is
visible that the exchange of 3-fluorophenyl substituent by (3-fluor-
ophenyl)ethyl moiety resulted in a more potent activity against 6 Hz-
induced seizures. Introduction of ethylene linker resulted also in an
increase of PI values to 16.6, which indicates that such a structural
modification has beneficial effect not only on the anticonvulsant ac-
tivity but also on the safety of compound 22.
2.3. ADME-Tox properties of compounds 17 and 22
Since toxicity studies constitute an important part of preclinical
testing of new drug candidates, the most promising drug candidates
(17, 22) were analyzed for their possible cytotoxic, genotoxic and he-
molytic effects. Cytotoxicity was monitored after 24 h incubation of
liver cells (NMu3Li, HepG2) and human embryonic kidney cells (HEK-
293) with the increased concentrations (0–125 µg/ml) of the in-
vestigated compounds. Although HepG2 cells have cancerous char-
acteristics, they retain many liver-specific functions and are widely
used for studying hepatotoxic properties of drugs and drug-candidates
[18]. According to the literature, toxicity threshold was defined as the
concentration of the compound at which the viability of cells decreased
by at least 30% [19]. Exceeding of this threshold for all of the tested cell
lines was observed above 16 µg/ml (Fig. 3). Pharmacokinetic (PK)
studies for compounds 17 and 22 were not performed yet, thus their in-
vivo concentrations are unknown. However, the maximal concentration
of the previously examined 5-(3-chlorobenzyl)-4-hexyl-2,4-dihydro-3H-
1,2,4-triazole-3-thione, structurally related to 17 and 22, in mouse
plasma was 4.232 µg/ml [7]. Therefore, it is likely that the above-
mentioned 1,2,4-triazole derivatives would be non-toxic for living cells
in concentrations necessary to generate the anticonvulsant effect in-
vivo.
Evaluation of genotoxic potential of 17 and 22 was performed using
a single cell gel electrophoresis (SCGE) technique, widely known as
comet assay. This method allows detection of DNA damages (e.g.,
single- and double-strand breaks, AP sites, DNA-DNA and DNA-protein
cross-links) in living cells exposed to the investigated factors [20]. The
main principle of the comet assay is based on different migration speeds
of damaged and undamaged DNA under electrophoretic conditions. The
presence and intensity of the comet tail reflect the number of DNA
breaks. As can be seen in Fig. 4, there have not been observed any
genotoxic changes in HEK-293 cells exposed to compounds 17 and 22
(10 µg/ml) for 24 h.
Finally, the assessment of hemolytic potential of these compounds
was performed by spectrophotometric measurement of hemoglobin
released from red blood cells (RBCs). Free hemoglobin may cause ser-
ious damage to kidneys, liver, heart and spleen [21]. It also exerts
neurotoxic activity which is mediated by heme [22]. Drug-induced lysis
of RBCs not only prevents i.v. administration of the drug but also in-
tensifies its toxicity when administered by other routes [23]. Although
toxic hemolysis caused by the antiepileptic drugs is rather rare [24], it
is desirable to exclude the risk of such side-effects in the case of each
drug candidate. Compounds 17 and 22 in concentrations non-toxic for
the cells evaluated in MTT assay (i.e. 5, 10, 15 µg/ml), were tested
during in-vitro hemolysis study. The investigated derivatives did not
produce statistically significant changes in the level of hemoglobin re-
leased to the medium (Table 6). Therefore, it can be concluded that the
most promising anticonvulsant drug candidates have no tendency to
disrupt membranes of RBCs.
3. Conclusions
Based on the results of MES and 6 Hz (32 mA) tests, a group of 4-
alkyl-5-substituted-1,2,4-triazole-3-thione derivatives with broad an-
ticonvulsant activity have been selected for further mechanistic and
ADME-Tox studies. The most promising compounds (17, 22) exhibited
strong anticonvulsant activity both in generalized tonic-clonic and
psychomotor seizures. These compounds did not induce genotoxic and
hemolytic changes in human cells as well as they were non-toxic for
living cells in concentrations less than 16 µg/ml. Taking into account
the structural requirements for good anticonvulsant activity of 4-alkyl-
5-aryl-1,2,4-triazole-3-thiones, it is visible that small EWGs attached to
phenyl ring have beneficial effects both on affinity towards VGSCs and
protective activity in the animal models of epilepsy.
4. Materials and methods
4.1. Chemistry
All reagents and solvents were purchased from Sigma-Aldrich and
were used without further purification. Melting points of the com-
pounds were measured using Fisher-Johns apparatus. NMR spectra of
the compounds dissolved in DMSO‑d6 were recorded on a 700 MHz
Bruker Avance II Plus spectrometer (Bruker BioSpin, Germany).
Chemical shifts were reported in parts per million (δ) in relation to
tetramethylsilane (TMS) as an internal standard. Elemental analyses
were performed on AMZ 851 CHX analyzer (PG, Gdańsk, Poland) and
the results were within ± 0.4% of the theoretical values. The results of
spectral characterization of the intermediates (i.e., 1,4-disubstituted
thiosemicarbazides) are given as Supplementary Material.
4.1.1. Synthesis of the compounds 1–22
Equimolar amounts of various alkyl isothiocyanates and carboxylic
acid hydrazides (obtained from the respective carboxylic acids) were
mixed together and heated to 110 °C until a product was formed (i.e.,
for 5 min). The obtained thiosemicarbazide derivatives were washed
with diethyl ether, filtered and crystallized from anhydrous ethanol.
These compounds were subsequently dissolved in 2% NaOH and heated
under reflux for 2 h. After cooling to room temperature, the solvent was
neutralized with 3 M HCl to form a solid of appropriate 4-alkyl-5-sub-
stituted-1,2,4-triazole-3-thione derivative, which was filtered, dried
Table 5
Comparison of the anticonvulsant activity, neurotoxicity and PI of compounds
17 and 22 with known AEDs.
Compound TPEa
[min]
ED50 MES
[mg/kg]
ED50 6 Hz
(32 mA) [mg/
kg]
TD50
[mg/kg]
PI (TD50/
ED50)
17 15 67.8 39.3 135.6 2.0 (MES)
3.4 (6 Hz)
22 15 87.5 18.6 309.3 3.5 (MES)
16.6 (6 Hz)
VPA 15 189.0 130.6 363.3 1.9 (MES)
2.8 (6 Hz)
CBZ 30 7.81b 47.9b 45.4b 5.8 (MES)
0.95 (6 Hz)
LEV 60 > 500b 19.4b > 500b > 25.8
(6 Hz)
1601c 82.5 (6 Hz)
Reference AEDs: valproate (VPA), carbamazepine (CBZ), levetiracetam (LEV); if
not otherwise stated – data taken from own experiments.
a TPE – time to peak of anticonvulsant activity.
b Data taken from [11].
c Data taken from [25] – experiments performed in our laboratory.
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and crystallized from anhydrous ethanol.
4.1.1.1. 4-Hexyl-5-(2-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-
thione (1). Yield: 59%, m.p. 86–88 °C, 1H NMR (700 MHz): 0.74 (t, 3H,
CH3, J= 7.2 Hz), 1.00–1.26 (m, 6H, 3CH2), 1.44–1.49 (m, 2H, CH2),
3.85 (t, 2H, CH2, J= 7.5 Hz), 6.95 (td, 1H, ArH, J= 7.4 Hz,
J= 1.1 Hz), 7.02 (dd, 1H, ArH, J= 8.2 Hz, J= 0.9 Hz), 7.30 (dd, 1H,
ArH, J= 7.6 Hz, J= 1.7 Hz), 7.40–7.43 (m, 1H, ArH), 10.30 (s, 1H,
OH), 13.78 (s, 1H, NH). 13C NMR (175 MHz): 14.20, 22.16, 25.76,
27.64, 30.81, 43.92, 113.90, 116.49, 119.79, 131.81, 132.83, 150.36,
156.28, 166.88. Anal. C14H19N3OS (C, H, N).
4.1.1.2. 4-Heptyl-5-(2-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-
thione (2). Yield: 48%, m.p. 72–74 °C, 1H NMR (700 MHz): 0.87 (t, 3H,
CH3, J= 7.1 Hz), 1.08–1.38 (m, 8H, 4CH2), 1.45–1.49 (m, 2H, CH2),
3.79 (t, 2H, CH2, J= 7.1 Hz), 7.04–7.54 (m, 4H, ArH), 10.26 (s, 1H,
Fig. 3. Toxicity of compounds 17 (upper graph) and 22 (lower graph) against NMu3Li, HepG2 and HEK-293 cells evaluated in MTT assay after 24 h incubation.
Fig. 4. Genotoxicity evaluation after 24 h treatment of HEK-293 cells with compounds 17 and 22 (10 µg/ml).
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OH), 13.78 (s, 1H, NH). 13C NMR (175 MHz): 14.06, 22.53, 25.22,
27.63, 27.92, 31.65, 47.81, 115.11, 117.60, 119.79, 122.90, 131.01,
145.44, 156.28, 170.27. Anal. C15H21N3OS (C, H, N).
4.1.1.3. 4-Hexyl-5-(3-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-
thione (3). Yield: 64%, m.p. 90–92 °C, 1H NMR (700 MHz): 0.78 (t, 3H,
CH3, J= 7.2 Hz), 1.10–1.19 (m, 6H, 3CH2), 1.46–1.51 (m, 2H, CH2),
3.95 (t, 2H, CH2, J= 7.3 Hz), 6.72–6.82 (m, 2H, ArH), 7.29–7.33 (m,
2H, ArH), 9.90 (s, 1H, OH), 14.00 (s, 1H, NH). 13C NMR (175 MHz):
12.11, 19.37, 21.65, 24.05, 27.79, 43.47, 111.78, 113.21, 118.30,
125.07, 127.97, 150.03, 156.87, 165.91. Anal. C14H19N3OS (C, H, N).
4.1.1.4. 4-Heptyl-5-(3-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-
thione (4). Yield: 52%, m.p. 86–88 °C, 1H NMR (700 MHz): 0.85 (t, 3H,
CH3, J= 7.2 Hz), 1.06–1.24 (m, 6H, 3CH2), 1.58–1.64 (m, 4H, 2CH2),
3.92 (t, 2H, CH2, J= 7.4 Hz), 6.94–6.97 (m, 1H, ArH), 7.25–7.35 (m,
3H, ArH), 10.05 (s, 1H, OH), 14.02 (s, 1H, NH). 13C NMR (175 MHz):
11.79, 19.64, 23.85, 25.05, 27.28, 32.54, 113.77, 115.40, 120.21,
124.81, 127.70, 150.06, 156.65, 166.58. Anal. C15H21N3OS (C, H, N).
4.1.1.5. 4-Hexyl-5-(4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-
thione (5). Yield: 55%, m.p. 86–88 °C, 1H NMR (700 MHz): 0.73 (t, 3H,
CH3, J= 7.2 Hz), 1.08–1.18 (m, 6H, 3CH2), 1.49–1.54 (m, 2H, CH2),
4.00 (t, 2H, CH2, J= 7.4 Hz), 6.92 (dd, 2H, ArH, J= 6.3 Hz,
J= 1.9 Hz), 7.47 (dd, 2H, ArH, J= 6.3 Hz, J= 1.9 Hz), 10.07 (s, 1H,
OH), 13.75 (s, 1H, NH). 13C NMR (175 MHz): 14.21, 22.26, 25.78,
27.80, 30.85, 43.91, 116.23, 117.33, 130.61, 152.00, 159.95, 167.29.
Anal. C14H19N3OS (C, H, N).
4.1.1.6. 4-Heptyl-5-(4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-
thione (6). Yield: 61%, m.p. 76–78 °C, 1H NMR (700 MHz): 0.90 (t, 3H,
CH3, J= 7.2 Hz), 1.07–1.27 (m, 6H, 3CH2), 1.64–1.72 (m, 4H, 2CH2),
4.10 (bs, 2H, CH2), 6.92 (dd, 2H, ArH, J= 6.3 Hz, J= 2.1 Hz), 7.42 (d,
2H, ArH, J= 6.2 Hz, J= 2.2 Hz), 10.21 (s, 1H, OH), 13.75 (s, 1H, NH).
13C NMR (175 MHz): 19.23, 25.19, 25.62, 25.94, 29.41, 32.36, 57.57,
114.47, 116.51, 117.73, 119.57, 132.42, 149.96, 157.09, 166.07. Anal.
C15H21N3OS (C, H, N).
4.1.1.7. 4-Butyl-5-(3-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-
thione (7). Yield: 80%, m.p. 94–96 °C, 1H NMR (700 MHZ): 0.71 (t, 3H,
CH3, J= 7.2 Hz), 1.10 (sext, 2H, CH2, J= 7.3 Hz), 1.40 (quint, 2H,
CH2, J= 7.1 Hz), 3.71 (s, 3H, OCH3), 3.96 (t, 2H, CH2, J= 7.3 Hz),
7.04–7.43 (m, 4H, ArH), 13.92 (s, 1H, NH). 13C NMR (175 MHz): 11.91,
19.58, 29.07, 43.46, 55.21, 112.11, 114.12, 118.44, 125.38, 127.30,
147.52, 159.84, 166.18. Anal. C13H17N3OS (C, H, N).
4.1.1.8. 4-Hexyl-5-(3-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-
thione (8). Yield: 89%, m.p. 118–120 °C, 1H NMR (700 MHz): 0.75 (t,
3H, CH3, J= 6.8 Hz), 1.01–1.20 (m, 6H, 3CH2), 1.40–1.58 (m, 2H,
CH2), 3.79 (s, 3H, OCH3), 4.01 (t, 2H, CH2, J= 7.5 Hz), 7.10–7.25 (m,
3H, ArH), 7.42–7.52 (m, 1H, ArH), 13.90 (s, 1H, NH). 13C NMR
(175 MHz): 11.39, 19.44, 22.97, 24.95, 28.05, 41.24, 53.07, 111.49,
114.18, 118.45, 125.12, 127.96, 148.71, 157.10, 164.67. Anal.
C15H21N3OS (C, H, N).
4.1.1.9. 5-(2-Bromophenyl)-4-butyl-2,4-dihydro-3H-1,2,4-triazole-3-
thione (9). Yield: 81%, m.p. 144–146 °C, 1H NMR (700 MHz): 0.67 (t,
3H, CH3, J= 7.3 Hz), 1.08 (sext, 2H, CH2, J= 7.3 Hz), 1.43 (quint, 2H,
CH2, J= 7.3 Hz), 3.76 (t, 2H, CH2, J= 7.4 Hz), 7.54 (m, 2H, ArH),
7.66–7.70 (m, 1H, ArH), 7.83–7.88 (m, 1H, ArH), 14.02 (s, 1H, NH).
13C NMR (175 MHz): 13.66, 19.38, 29.96, 43.69, 123.81, 127.79,
128.69, 133.13, 133.50, 133.55, 150.33, 167.13. Anal. C12H14BrN3S
(C, H, N).
4.1.1.10. 5-(2-Bromophenyl)-4-pentyl-2,4-dihydro-3H-1,2,4-triazole-3-
thione (10). Yield: 88%, m.p. 154–156 °C, 1H NMR (700 MHz): 0.70 (t,
3H, CH3, J= 6.9 Hz), 1.01–1.10 (m, 4H, 2CH2), 1.39–1.50 (m, 2H,
CH2), 3.76 (t, 2H, CH2, J= 7.5 Hz), 7.53–7.63 (m, 2H, ArH), 7.66–7.70
(m, 1H, ArH), 7.83–7.88 (m, 1H, ArH), 14.02 (s, 1H, NH). 13C NMR
(175 MHz): 13.99, 21.76, 27.43, 28.14, 43.89, 123.80, 127.80, 128.68,
133.12, 133.51, 133.55, 150.31, 167.11. Anal. C13H16BrN3S (C, H, N).
4.1.1.11. 5-(3-Bromophenyl)-4-butyl-2,4-dihydro-3H-1,2,4-triazole-3-
thione (11). Yield: 81%, m.p. 106–108 °C, 1H NMR (700 MHz): 0.74 (t,
3H, CH3, J= 7.3 Hz), 1.05–1.19 (m, 2H, CH2), 1.43–1.55 (m, 2H, CH2),
4.02 (t, 2H, CH2, J= 7.6 Hz), 7.53 (t, 1H, ArH, J= 7.8 Hz), 7.68–7.73
(m, 1H, ArH), 7.79–7.84 (m, 1H, ArH), 7.91 (t, 1H, ArH, J= 1.7 Hz),
14.00 (s, 1H, NH). 13C NMR (175 MHz): 13.69, 19.45, 29.95, 43.82,
122.56, 128.21, 128.88, 131.65, 131.69, 134.12, 150.29, 167.70. Anal.
C12H14BrN3S (C, H, N).
4.1.1.12. 5-(3-Bromophenyl)-4-pentyl-2,4-dihydro-3H-1,2,4-triazole-3-
thione (12). Yield: 88%, m.p. 108–110 °C, 1H NMR (700 MHz): 0.74 (t,
3H, CH3, J= 6.9 Hz), 1.03–1.19 (m, 4H, 2CH2), 1.53 (t, 2H, CH2,
J= 7.3 Hz), 4.01 (t, 2H, CH2, J= 7.6 Hz), 7.53 (t, 1H, ArH,
J= 7.9 Hz), 7.68–7.73 (m, 1H, ArH), 7.79–7.84 (m, 1H, ArH), 7.90
(t, 1H, ArH, J= 1.6 Hz), 14.00 (s, 1H, NH). 13C NMR (175 MHz): 14.06,
21.76, 27.45, 28.23, 44.00, 122.66, 128.21, 128.89, 131.67, 134.10,
134.11, 150.28, 167.69. Anal. C13H16BrN3S (C, H, N).
4.1.1.13. 5-(4-Bromophenyl)-4-butyl-2,4-dihydro-3H-1,2,4-triazole-3-
thione (13). CAS: 701946-13-6, yield: 68%, m.p. 128–130 °C, 1H NMR
(700 MHz): 0.74 (t, 3H, CH3, J= 7.3 Hz), 1.12 (sext, 2H, CH2,
J= 7.3 Hz), 1.49 (quint, 2H, CH2, J= 7.2 Hz), 4.02 (t, 2H, CH2,
J= 7.5 Hz), 7.64 (dd, 2H, ArH, J= 2.0 Hz, J= 6.6 Hz), 7.77 (dd, 2H,
ArH, J= 1.9 Hz, J= 6.6 Hz), 13.99 (s, 1H, NH). 13C NMR (175 MHz):
13.75, 19.48, 30.03, 43.87, 124.93, 125.92, 131.10, 132.61, 150.78,
167.73. Anal. C12H14BrN3S (C, H, N).
4.1.1.14. 5-(4-Bromophenyl)-4-pentyl-2,4-dihydro-3H-1,2,4-triazole-3-
thione (14). Yield: 81%, m.p. 124–126 °C, 1H NMR (700 MHz): 0.74 (t,
3H, CH3, J= 7.1 Hz), 1.02–1.19 (m, 4H, 2CH2), 1.50 (quint, 2H, CH2,
J= 7.3 Hz), 4.01 (t, 2H, CH2, J= 7.6 Hz), 7.64 (dd, 2H, ArH,
J= 2.1 Hz, J= 6.6 Hz), 7.78 (dd, 2H, ArH, J= 1.9 Hz, J= 6.6 Hz),
13.98 (s, 1H, NH). 13C NMR (175 MHz): 14.10, 21.85, 27.52, 28.27,
44.03, 124.92, 125.93, 131.11, 132.60, 150.77, 167.71. Anal.
C13H16BrN3S (C, H, N).
4.1.1.15. 4-Butyl-5-(3-fluorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-
thione (15). Yield: 78%, m.p. 70–72 °C, 1H NMR (700 MHz): 0.74 (t,
3H, CH3, J= 7.4 Hz), 1.13 (sext, 2H, CH2, J= 7.3 Hz), 1.49 (quint, 2H,
CH2, J= 7.4 Hz), 4.02 (t, 2H, CH2, J= 7.5 Hz), 7.44–7.66 (m, 4H,
ArH), 14.00 (s, 1H, ArH). 13C NMR (175 MHz): 13.69, 19.42, 29.98,
43.82, 116.12 (d, J= 23.52 Hz), 118.24 (d, J= 21.09 Hz), 125.40 (d,
Table 6
Hemolytic activity of compounds 17 and 22 in human red blood cells.
Hemolysis (%)
Compound 17 (µg/ml)
5 0.05 ± 0.035
10 0.174 ± 0.070
15 0.187 ± 0.053
Compound 22 (µg/ml)
5 0.028 ± 0.067
10 0.133 ± 0.004
15 0.182 ± 0.059
PBS treated erythrocytes (control group) 0.025 ± 0.001
0.1% Triton-X 100.21 ± 0.31
Results were expressed as mean ± SD from 3 independent experiments.
Results were designated as statistically significant (ANOVA with post-hoc Tukey
test) when p < 0.05 (vs. control group).
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J= 2.9 Hz), 128.69 (d, J= 8.5 Hz), 131.84 (d, J= 8.6 Hz), 150.47,
161.80 (d, J= 245.4 Hz), 167.80. Anal. C12H14FN3S (C, H, N).
4.1.1.16. 5-(3-Fluorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-
thione (16). CAS: 54543-33-8, yield: 76%, m.p. 76–78 °C, 1H NMR
(700 MHz): 0.77 (t, 3H, CH3, J= 7.1 Hz), 1.07–1.17 (m, 6H, 3CH2),
1.47–1.54 (m, 2H, CH2), 3.88 (t, 2H, CH2, J= 7.3 Hz), 7.45–7.67 (m,
4H, ArH), 13.99 (s, 1H, NH). 13C NMR (175 MHz): 14.19, 22.20, 25.70,
27.68, 30.80, 43.98, 116.17 (d, J= 23.1 Hz), 118.24 (d, J= 21.0 Hz),
125.44 (d, J= 2.9 Hz), 128.80 (d, J= 8.6 Hz), 131.83 (d, J= 8.5 Hz),
150.44, 162.48 (d, J= 243.8 Hz), 167.75. Anal. C14H18FN3S (C, H, N).
4.1.1.17. 5-(3-Fluorophenyl)-4-heptyl-2,4-dihydro-3H-1,2,4-triazole-3-
thione (17). Yield: 79%, m.p. 64–66 °C, 1H NMR (700 MHz): 0.80 (t,
3H, CH3, J= 7.3 Hz), 1.06–1.20 (m, 8H, 4CH2), 1.50 (quint, 2H, CH2,
J= 7.2 Hz), 4.05 (t, 2H, CH2, J= 7.5 Hz), 7.44–7.66 (m, 4H, ArH),
13.99 (s, 1H, NH). 13C NMR (175 MHz): 14.31, 22.38, 25.97, 27.71,
28.26, 31.34, 43.98, 116.19 (d, J= 24.0 Hz), 118.23 (d, J= 22.4 Hz),
125.44 (d, J= 2.9 Hz), 128.80 (d, J= 8.6 Hz), 131.81 (d, J= 8.5 Hz),
150.48, 162.49 (d, J= 246.7 Hz), 167.77. Anal. C15H20FN3S (C, H, N).
4.1.1.18. 4-Butyl-5-[(3-fluorophenyl)methyl]-2,4-dihydro-3H-1,2,4-
triazole-3-thione (18). Yield: 76%; m.p. 76–78 °C, 1H NMR (700 MHz):
0.81 (t, 3H, CH3, J= 7.3 Hz), 1.22 (sext, 2H, CH2, J= 7.5 Hz),
1.31–1.37 (m, 2H, CH2), 3.84 (t, 2H, CH2, J= 7.8 Hz), 4.16 (s, 2H,
CH2), 7.10–7.41 (m, 4H, ArH), 13.60 (s, 1H, NH). 13C NMR (175 MHz):
13.91, 19.71, 29.87, 30.86, 43.46, 114.41 (d, J= 20.6 Hz), 116.24 (d,
J= 22.3 Hz), 125.46 (d, J= 2.8 Hz), 131.08 (d, J= 8.5 Hz), 138.38 (d,
J= 2.8 Hz), 151.26, 162.67 (d, J= 243.2 Hz), 167.22. Anal.
C13H16FN3S (C, H, N).
4.1.1.19. 5-[(3-Fluorophenyl)methyl]-4-hexyl-2,4-dihydro-3H-1,2,4-
triazole-3-thione (19). Yield: 82%, m.p. 122–124 °C, 1H NMR
(700 MHz): 0.83 (t, 3H, CH3, J= 7.2 Hz), 1.12–1.25 (m, 6H, 3CH2),
1.34 (quint, 2H, CH2, J= 7.7 Hz), 3.83 (t, 2H, CH2, J= 7.8 Hz), 4.15 (s,
2H, CH2), 7.09–7.42 (m, 4H, ArH), 13.60 (s, 1H, NH). 13C NMR
(175 MHz): 14.28, 22.31, 26.00, 27.67, 30.83, 31.18, 43.69, 114.43
(d, J= 20.9 Hz), 116.22 (d, J= 21.7 Hz), 125.42, 131.08 (d,
J= 8.4 Hz), 138.42 (d, J= 7.8 Hz), 151.46, 162.74 (d, J= 245.2 Hz),
167.22. Anal. C15H20FN3S (C, H, N).
4.1.1.20. 5-[(3-Fluorophenyl)methyl]-4-heptyl-2,4-dihydro-3H-1,2,4-
triazole-3-thione (20). Yield: 84%, m.p. 82–84 °C, 1H NMR (700 MHz):
0.85 (t, 3H, CH3, J= 7.3 Hz), 1.13–1.19 (m, 6H, 3CH2), 1.23 (sext, 2H,
CH2, J= 7.1 Hz), 1.26–1.35 (m, 2H, CH2), 3.83 (t, 2H, CH2,
J= 7.9 Hz), 4.16 (s, 2H, CH2), 7.05–7.19 (m, 3H, ArH), 7.37–7.42
(m, 1H, ArH), 13.60 (s, 1H, NH). 13C NMR (175 MHz): 14.39, 22.43,
26.29, 27.71, 28.61, 30.82, 31.48, 43.69, 114.42 (d, J= 21.1 Hz),
116.19 (d, J= 21.7 Hz), 125.40 (d, J= 2.5 Hz), 131.08 (d, J= 8.3 Hz),
138.42 (d, J= 7.8 Hz), 151.17, 162.75 (d, J= 244.8 Hz), 167.23. Anal.
C16H22FN3S (C, H, N).
4.1.1.21. 4-Butyl-5-[2-(3-fluorophenyl)ethyl]-2,4-dihydro-3H-1,2,4-
triazole-3-thione (21). Yield: 88%, m.p. 86–88 °C, 1H NMR (700 MHz):
0.88 (t, 3H, CH3, J= 7.4 Hz), 1.28 (sext, 2H, CH2, J= 7.5 Hz),
1.54–1.59 (m, 2H, CH2), 2.98–3.04 (m, 4H, 2CH2), 3.88 (t, 2H, CH2,
J= 7.7 Hz), 7.00–7.04 (m, 1H, ArH), 7.11–7.17 (m, 2H, ArH),
7.31–7.34 (m, 1H, ArH), 13.50 (s, 1H, NH). 13C NMR (175 MHz):
14.00, 19.80, 26.37, 30.23, 31.23, 43.04, 113.44 (d, J= 21.2 Hz),
115.70 (d, J= 21.2 Hz), 125.09 (d, J= 2.6 Hz), 130.60 (d, J= 8.5 Hz),
143.76 (d, J= 7.5 Hz), 151.90, 162.70 (d, J= 242.7 Hz), 166.80. Anal.
C14H18FN3S (C, H, N).
4.1.1.22. 5-[2-(3-Fluorophenyl)ethyl]-4-hexyl-2,4-dihydro-3H-1,2,4-
triazole-3-thione (22). Yield: 90%, m.p. 64–66 °C, 1H NMR (700 MHz):
0.82 (t, 3H, CH3, J= 6.4 Hz), 1.15–1.33 (m, 6H, 3CH2), 1.43–1.65 (m,
2H, CH2), 2.90–3.06 (m, 4H, 2CH2), 3.85 (t, 2H, CH2, J= 7.6 Hz),
6.94–7.94 (m, 4H, ArH), 13.50 (s, 1H, NH). 13C NMR (175 MHz): 11.54,
19.63, 23.32, 23.56, 25.25, 28.40, 40.40, 110.69 (d, J= 20.9 Hz),
112.89 (d, J= 20.9 Hz), 122.28 (d, J= 2.7 Hz), 127.82 (d, J= 8.4 Hz),
141.00 (d, J= 7.6 Hz), 149.11, 159.76 (d, J= 242.4 Hz), 163.97. Anal.
C16H22FN3S (C, H, N).
4.2. Animal experimentations
All animal experiments were performed in accordance with EU
Directive 2010/63/EU for animal experiments and complied with the
ARRIVE guidelines. All the procedures were also approved by the Local
Ethics Committee (Lublin, Poland, No. of approvals: 102/2017, 19/
2018, 65/2018, 87/2018).
4.2.1. MES test
Anticonvulsant activity of the investigated compounds was de-
termined according to the same procedure as described in [4,5,7]. Ex-
periments were conducted on adult Swiss albino mice weighing
20–25 g. The animals were kept in colony cages with free access to food
and tap water. After one week of acclimatization, the animals were
randomly divided into groups consisting of 8 mice. The investigated
compounds were suspended in a 1% solution of Tween 80 in distilled
water and administered i.p. in a volume of 5 ml/kg. During experiment,
the compounds were administered i.p. in a fixed dose of 300 mg/kg at
four pretreatment times (15, 30, 60, 120 min) before the MES test.
Electroconvulsions were produced by an alternating current (0.2 s sti-
mulus duration; 500 V, 50 Hz, fixed current intensity of 25 mA) deliv-
ered via ear-clip electrodes by a Type 221 Rodent Shocker generator
(Hugo Sachs Elektronik, Freiburg, Germany). The abolition of a hind-
limb tonic extension was taken as a criterion of the anticonvulsant
activity. Next, the active compounds (i.e., the compounds that ex-
hibited anticonvulsant effect in a dose of 300 mg/kg) were adminis-
tered in increasing doses in order to calculate ED50 values using the log-
probit method by Litchfield and Wilcoxon.
4.2.2. 6 Hz test
Psychomotor (limbic) seizures in mice were evoked by current
(6 Hz, 0.2 ms rectangular pulse width, 32 mA, 3 s duration) generated
by an S48 Square Pulse Stimulator and CCU1 Constant Current Unit
(Grass Technologies, West Warwick, RI, USA). After application of
ocular anesthetic (0.5% solution of tetracaine hydrochloride) to the
mouse corneas, the animals treated with the increasing concentrations
of 17 and 22 underwent corneal stimulation and were placed separately
in plexiglas cages (25 × 15 × 10 cm) for the observation of the pre-
sence or absence of psychomotor seizures. Immediately following the
6 Hz corneal stimulation the animals exhibited a “stunned” posture
associated with rearing and automatic movements that lasted from 60
to 120 s in untreated animals [11]. The mice were considered to be
protected from seizures if they resumed their normal exploratory be-
havior within 20 s after stimulation. The anticonvulsant activity was
evaluated as the ED50 value (median effective dose of the compound,
which protects 50% of mice against convulsions) calculated from the
log-probit method according to Litchfield and Wilcoxon.
4.2.3. Rotarod test
Motor coordination impairment (acute neurotoxicity) after i.p. ad-
ministration of the investigated compounds to mice was examined
using the rotarod test as described in [25]. Neurotoxicity of the tested
compounds is presented as median toxic doses (TD50) that impair motor
coordination in 50% of the mice challenged with the rotarod test.
4.3. PAMPA-BBB assay
Blood-brain barrier (BBB) permeability of the compounds was in-
vestigated using a PAMPA method (parallel artificial membrane
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permeability assay). The PAMPA system consisted of a 96-well micro-
filter plate was divided into two chambers: a donor at the bottom and
an acceptor at the top, separated by a 120-μm-thick microfilter disc
coated with BBB lipid solution (Pion, Inc.). The solutions of each
compound were prepared in dimethyl sulfoxide (DMSO) at 4 mg/ml
concentration and then diluted with Prisma buffer (pH = 7.4) to obtain
the donor drug solution with the final nominal concentration of 20 µg/
ml. The donor solutions were placed in donor plate. Acceptor plate
contained Brain Sink Buffer (BSB). The plates were put together and
incubated at 37 °C for 180 min in a humidity-saturated atmosphere. The
concentrations of the respective compounds were determined with a
UV-reader (Multiskan GO, Thermo Scientific) at 254 nm in the donor
and acceptor compartments.
The permeability coefficient values (Pe) were calculated by using
the following equation:
=
× + ×
( )
( )P
ln
S t
1
e
C
C
V V
1 1
A
equilibrium
D A
where VD– donor volume, VA – acceptor volume, Cequilibrium – equili-
brium concentration, = × + ×+Cequilibrium
C V C V
V V
D D A A
D A
, CD – donor concentra-
tion, CA – acceptor concentration, S – membrane area, t – incubation
time (in seconds).
4.4. Radioligand binding assay
Radioligand binding studies with [3H]batrachotoxin were per-
formed using the same procedure as described in our previous paper
[6].
4.5. Cellular toxicity evaluation
Toxicity of the compounds was analyzed using MTT assay on
murine (NMu3Li) and human (HepG2, HEK-293) cells. Experiments
were performed in accordance with the international standard ISO-
10993-5:2009. HEK-293 (human embryonic kidney) cells grew in
Minimal Essential Medium (MEM; Sigma-Aldrich, Saint Louis, MO,
USA), HepG2 (hepatocellular carcinoma) cells were cultured in Eagle’s
Minimal Essential Medium containing L-glutamine (Sigma-Aldrich),
while NMu3Li cells were cultivated in DMEM-high glucose (Sigma
Aldrich). All media were supplemented with 10% fetal bovine serum
(FBS, Sigma Aldrich), 100 U/mL of penicillin and 100 mg/mL of
streptomycin (PenStrep, Sigma Aldrich). Procedure of MTT test was
described in details in our previously published paper [7]. Experiments
were repeated twice, and the measurements in each experiment were
run in quadruplicate.
4.6. Hemolytic activity evaluation
Human red blood cells (RBCs) concentrate was obtained from the
Regional Blood Donation and Transfusion Centre (Lublin, Poland).
About 5 ml of RBCs concentrate was washed three times with sterile
PBS and each time centrifuged at 1500 rpm for 3 min. The obtained
pellet was resuspended using sterile PBS in order to obtain 2% sus-
pension of RBCs. A volume of 1 ml of RBCs suspension was mixed with
1 ml of different concentrations of the investigated compounds. The
mixtures were incubated at 37 °C for 30 min and centrifuged at
2500 rpm for 10 min. The amount of free hemoglobin in supernatants
was measured spectrophotometrically at 405 nm. Negative and positive
controls were performed by incubating RBCs with sterile PBS and 0.1%
Triton-X, respectively. Each experiment was run in triplicate.
4.7. Genotoxicity evaluation
Assessment of DNA damages in HepG2 cells was performed using
OxiSelect Comet Assay Kit (Cell Biolabs, Inc.) according to the manu-
facturer’s protocol. HepG2 cells (1 × 105 cells/ml in ice-cold phosphate
buffer saline) previously exposed (for 24 h) to compounds 17 and 22
(10 µg/ml) were mixed with liquefied low melting agarose and trans-
ferred onto the Oxiselect comet slide. After storing for 15 min at 4 °C,
the slides were immersed in a chilled Lysis Buffer (for 45 min at 4 °C, in
the dark) and Alkaline Solution (for 30 min at 4 °C, in the dark). Next,
the Alkaline Solution was replaced with pre-chilled TBE electrophoresis
solution. After immersing for 5 min, the slides were transferred into the
horizontal electrophoresis chamber and covered with TBE electro-
phoresis buffer. The electrophoresis was run for 15 min at 1 V/cm. DNA
released from the cells was stained with Vista Green DNA Dye for
15 min at room temparature and observed under fluorescence micro-
scope (Olympus BX63). The images of cells were captured using XM10
digital camera (Olympus).
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